Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385580 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT00385580 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 94 participants.
The verdict
NCT00385580, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.
Interventions
- DRUG dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385580
The ClinicalTrials.gov registry entry for NCT00385580 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dasatinib is the first listed.
NCT00385580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385580 about?
NCT00385580 is a clinical study titled "Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer". The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this tre...
What is the current status of trial NCT00385580?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2007-01. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00385580?
The interventions under investigation include: dasatinib (DRUG).
Who is sponsoring clinical trial NCT00385580?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.